Lakefront Biotherapeutics American Depositary Shares
LKFT
69 hedge funds and large institutions have $1.03B invested in Lakefront Biotherapeutics American Depositary Shares in 2017 Q3 according to their latest regulatory filings, with 11 funds opening new positions, 20 increasing their positions, 29 reducing their positions, and 18 closing their positions.
11% more capital invested
Capital invested by funds: $922M → $1.03B (+$105M)
3.86% less ownership
Funds ownership: 23.69% → 19.83% (-3.9%)
10% less call options, than puts
Call options by funds: $849K | Put options by funds: $947K
12% less funds holding
Funds holding: 78 → 69 (-9)
31% less repeat investments, than reductions
Existing positions increased: 20 | Existing positions reduced: 29
39% less first-time investments, than exits
New positions opened: 11 | Existing positions closed: 18
67% less funds holding in top 10
Funds holding in top 10: 3 → 1 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
O
OrbiMed
New York
|
+$21M |
| 2 |
FCM
Farallon Capital Management
San Francisco,
California
|
+$20.6M |
| 3 |
OMC
Old Mission Capital
Chicago,
Illinois
|
+$3.35M |
| 4 |
JP Morgan Chase
New York
|
+$2.62M |
| 5 |
ACM
Atika Capital Management
New York
|
+$2.45M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$66.1M |
| 2 |
EC
EcoR1 Capital
San Francisco,
California
|
-$29.5M |
| 3 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
-$22.9M |
| 4 |
Renaissance Technologies
New York
|
-$17.4M |
| 5 |
Sands Capital Management
Arlington,
Virginia
|
-$8.95M |
LKFT Hedge Fund Activity: Q3 2017 in Review
69 of the 4,012 institutional investors tracked by Wall St. Rank reported a position in Lakefront Biotherapeutics American Depositary Shares (LKFT) for Q3 2017, worth a combined $1.03B — up 11% from $922M a quarter earlier.
Sellers outnumbered buyers: 18 funds closed out of LKFT and 11 opened new positions — a net loss of 7 holders — while 29 trimmed existing stakes and 20 added.
The largest buyer was OrbiMed, adding an estimated $21M. The largest seller was Fidelity Investments, cutting an estimated $66.1M.
- 69 institutional investors held Lakefront Biotherapeutics American Depositary Shares (LKFT) as of Q3 2017, down from 78 in Q2 2017.
- Funds reported $1.03B of Lakefront Biotherapeutics American Depositary Shares stock for Q3 2017, up 11% quarter-over-quarter.
- 11 funds opened new Lakefront Biotherapeutics American Depositary Shares positions in Q3 2017 and 18 closed out, a net change of -7 holders.
- The largest Lakefront Biotherapeutics American Depositary Shares buyer in Q3 2017 was OrbiMed, an estimated $21M added.
- The largest Lakefront Biotherapeutics American Depositary Shares seller in Q3 2017 was Fidelity Investments, an estimated $66.1M sold.
Based on aggregated 13F filings for Q3 2017.